2025 was another successful year for Siegfried. How would you summarize it?

In 2025, Siegfried reported a strong financial performance, delivering across all key financial metrics. The continued and disciplined execution of our EVOLVE⁺ strategy enabled us to outpace market growth in many of our key segments. Backed by a diversified customer base, the strong commitment of our teams and our efficient operations, we further strengthened our position as a leading CDMO in the pharmaceutical industry and are well prepared to capitalize on the long-term trends shaping our markets.

What progress was made on Siegfried’s EVOLVE⁺ strategy in 2025?

In 2025, we continued to make solid progress in executing our EVOLVE⁺ strategy by expanding in targeted technologies and capacities that position Siegfried for sustainable growth. Across our network, we focused on areas where we see strong and lasting customer demand. In Spain, we are expanding sterile eye drop production at our El Masnou site in addition to the ongoing expansion of the sterile ophthalmic ointments manufacturing line. In Barberà del Vallès, we are strengthening our spray drying capabilities and in Hameln, the expansion of our fill-finish operations continues. Beyond these expansions, DINAMIQS inaugurated its new manufacturing facility for viral vectors and we have started to transfer the first products into our new high-volume drug substance plant in Minden. Together, these achievements underline our disciplined execution of EVOLVE⁺ and our commitment to building capabilities that support our customers’ long-term needs.

What makes Siegfried a sustainability leader in the CDMO industry?

Siegfried embeds sustainability into our core values and operations. In 2025, we became one of the first CDMOs to have net zero targets validated by the Science Based Targets initiative. We already started to take action in 2025 to fulfill this commitment, launching several decarbonization initiatives and establishing a solvent recovery taskforce to reduce waste at the four sites contributing the most of our Scope 1 emissions, ensuring that our decarbonization efforts are focused where they deliver the greatest impact.

We uphold the principles of the UN Global Compact, as a member company since 2022, and are consistently recognized with top-tier ESG ratings. This includes our inclusion in the Dow Jones Best-In-Class Europe Index and the S&P Global Sustainability Yearbook 2025. These achievements reflect our unwavering commitment to sustainability leadership.

Where do you see further opportunities for growth in the CDMO market?

We continue to see attractive growth opportunities across all segments of the CDMO market, driven by structural, long-term trends in pharmaceutical innovation and manufacturing. Innovation is increasingly coming from small and mid-size pharmaceutical companies. Today, more than 80% of new molecules in the global development pipeline are owned by these companies. Many of them do not have in-house development and manufacturing capabilities, as building and operating production facilities would be too capital-intensive and carry significant risk. As a result, they rely on high-quality CDMOs to scale their innovations efficiently from development to commercial production. This is why size really matters, because we are able to offer such integrated services from our comprehensive global network.

At the same time, small molecules remain the backbone of the industry. They continue to dominate late-stage development and approvals, and they represent the largest share of the global CDMO market. Many of these molecules are becoming increasingly complex, and manufacturing routes are longer, more intricate, and less forgiving. This makes it essential to have the right expertise, technologies, and scalable capacity in place early to avoid delays and de-risk development. Combined with the ongoing outsourcing trend across the pharmaceutical industry, this creates sustained demand for integrated, reliable manufacturing partners.

This is precisely where our EVOLVE⁺ strategy positions Siegfried strongly. By offering deep expertise, scalable capacity, and an integrated beginning-to-end platform, we are well placed to support our customers’ growth and to capitalize on these long-term market dynamics. As a result, we remain confident in our ability to grow above market across all segments we operate in.

What are you looking forward to in 2026?

I’m particularly looking forward to fully realizing the full value of our recent transaction. This acquisition is a major milestone in the execution of our EVOLVE⁺ strategy, expanding both our presence and our capacity in the US – the world’s largest pharmaceutical market. The combined capacity and expertise of these sites further strengthen our position as a leading CDMO for small-molecule drug substances, and I’m excited to achieve this together with our new colleagues. Building on our experience integrating the Novartis and BASF sites, we are already making good progress to bring the new sites on board quickly once the transaction closes later this year.